Arecor fully funded and gearing up to take flagship diabetes drug into clinic

Sarah Howell, chief executive of Arecor, tells Proactive London's Andrew Scott they have a dual business model - there's a technology business where they partner with major pharmaceutical companies, taking their products in-house, apply their technology to deliver back to them an improved product profile and she says that's been very successful .. profitable in its own right and with the upside potential of royalties.

The other side of the business is focused on developing their own portfolio of drugs, initially focused on the diabetes therapeutic area.

''We know that from working with major pharma that we can deliver products that they are unable to develop themselves ... so there is room for a company like Arecor''.

''Ultimately for some of these products for major markets such as insulin we'll look to partner for late stage commercialisation ... so yes we're competing with them but we also see them as partners moving forward''.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...



Full interview: Co-Diagnostics expects to win a CE mark-validated...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the Utah-based company expects to achieve a CE mark validation on its coronavirus detection test from the European Union by as early as next week. Egan says the company is very enthused by the entire process of the development...

2 days, 10 hours ago

2 min read